Two UK-based academics have devised a way to invent new medicines and get them to market at a fraction of the cost charged by big drug corporations, enabling millions in poor countries to be cured of infectious diseases and potentially slashing the NHS drugs bill.

The action would target the colossal action across Whitehall over pay, conditions and services. The action would be the first national strike

Once the drugs have passed through clinical trials and are licensed in India, the same data could be used to obtain a European licence so that they could be sold to the NHS as well.

Professor Shaunak says it is time that the monopoly on drug invention and production by multinational corporations – which charge high prices because they need to make big profits for their shareholders – was broken.

"The pharmaceutical industry has convinced us that we have to spend billions of pounds of invent each drug," he said. "We have spent a few millions. Yes, it will be a threat to the monopoly that there is.

"I`m not only an inventor of medicines – I`m an end user. We have become so completely dependent on the big pharmaceutical industry to provide all the medicines we use.

"Why should we be completely dependent on them when we do all the creative stuff in the universities? Maybe the time has come to say why can`t somebody else do it? What we have been struck by is that once we have started to do it, it is not so difficult."

The team`s work on the hepatitis C drug has formidable intellectual property. The drug is the first new medication in five years to enter clinical trials and has been licensed in India, supplying the Indian government, for hepatitis C – if clinical trials in Asia – if clinical trials in Asia

One industry insider envisaged legal challenges if the new drugs were not genuinely innovative. It could become "a huge intellectual property issue", he said.

The action was to be urged to send the British and Irish Chambers of Commerce which are the employers` organisations who travel to them and who have started to do it, it is not so difficult."

"Why should we be completely dependent on them when we do all the creative stuff in the universities? Maybe the time has come to say why can`t somebody else do it? What we have been struck by is that once we have started to do it, it is not so difficult."

The team`s work on the hepatitis C drug has formidable intellectual property. The drug is the first new medication in five years to enter clinical trials and has been licensed in India, supplying the Indian government, for hepatitis C – if clinical trials in Asia

One industry insider envisaged legal challenges if the new drugs were not genuinely innovative. It could become "a huge intellectual property issue", he said.

Indian-backed approach could aid poor nations and cut NHS bills

Once the drugs have passed through clinical trials and are licensed in India, the same data could be used to obtain a European licence so that they could be sold to the NHS as well.

Professor Shaunak says it is time that the monopoly on drug invention and production by multinational corporations – which charge high prices because they need to make big profits for their shareholders – was broken.

"The pharmaceutical industry has convinced us that we have to spend billions of pounds of invent each drug," he said. "We have spent a few millions. Yes, it will be a threat to the monopoly that there is.

"I`m not only an inventor of medicines – I`m an end user. We have become so completely dependent on the big pharmaceutical industry to provide all the medicines we use.

"Why should we be completely dependent on them when we do all the creative stuff in the universities? Maybe the time has come to say why can`t somebody else do it? What we have been struck by is that once we have started to do it, it is not so difficult."

The team`s work on the hepatitis C drug has formidable intellectual property. The drug is the first new medication in five years to enter clinical trials and has been licensed in India, supplying the Indian government, for hepatitis C – if clinical trials in Asia

One industry insider envisaged legal challenges if the new drugs were not genuinely innovative. It could become "a huge intellectual property issue", he said.

Indian-backed approach could aid poor nations and cut NHS bills

Once the drugs have passed through clinical trials and are licensed in India, the same data could be used to obtain a European licence so that they could be sold to the NHS as well.

Professor Shaunak says it is time that the monopoly on drug invention and production by multinational corporations – which charge high prices because they need to make big profits for their shareholders – was broken.

"The pharmaceutical industry has convinced us that we have to spend billions of pounds of invent each drug," he said. "We have spent a few millions. Yes, it will be a threat to the monopoly that there is.

"I`m not only an inventor of medicines – I`m an end user. We have become so completely dependent on the big pharmaceutical industry to provide all the medicines we use.

"Why should we be completely dependent on them when we do all the creative stuff in the universities? Maybe the time has come to say why can`t somebody else do it? What we have been struck by is that once we have started to do it, it is not so difficult."

The team`s work on the hepatitis C drug has formidable intellectual property. The drug is the first new medication in five years to enter clinical trials and has been licensed in India, supplying the Indian government, for hepatitis C – if clinical trials in Asia

One industry insider envisaged legal challenges if the new drugs were not genuinely innovative. It could become "a huge intellectual property issue", he said.

Once the drugs have passed through clinical trials and are licensed in India, the same data could be used to obtain a European licence so that they could be sold to the NHS as well.

Professor Shaunak says it is time that the monopoly on drug invention and production by multinational corporations – which charge high prices because they need to make big profits for their shareholders – was broken.

"The pharmaceutical industry has convinced us that we have to spend billions of pounds of invent each drug," he said. "We have spent a few millions. Yes, it will be a threat to the monopoly that there is.

"I`m not only an inventor of medicines – I`m an end user. We have become so completely dependent on the big pharmaceutical industry to provide all the medicines we use.

"Why should we be completely dependent on them when we do all the creative stuff in the universities? Maybe the time has come to say why can`t somebody else do it? What we have been struck by is that once we have started to do it, it is not so difficult."

The team`s work on the hepatitis C drug has formidable intellectual property. The drug is the first new medication in five years to enter clinical trials and has been licensed in India, supplying the Indian government, for hepatitis C – if clinical trials in Asia

One industry insider envisaged legal challenges if the new drugs were not genuinely innovative. It could become "a huge intellectual property issue", he said.

Once the drugs have passed through clinical trials and are licensed in India, the same data could be used to obtain a European licence so that they could be sold to the NHS as well.

Professor Shaunak says it is time that the monopoly on drug invention and production by multinational corporations – which charge high prices because they need to make big profits for their shareholders – was broken.

"The pharmaceutical industry has convinced us that we have to spend billions of pounds of invent each drug," he said. "We have spent a few millions. Yes, it will be a threat to the monopoly that there is.

"I`m not only an inventor of medicines – I`m an end user. We have become so completely dependent on the big pharmaceutical industry to provide all the medicines we use.

"Why should we be completely dependent on them when we do all the creative stuff in the universities? Maybe the time has come to say why can`t somebody else do it? What we have been struck by is that once we have started to do it, it is not so difficult."

The team`s work on the hepatitis C drug has formidable intellectual property. The drug is the first new medication in five years to enter clinical trials and has been licensed in India, supplying the Indian government, for hepatitis C – if clinical trials in Asia

One industry insider envisaged legal challenges if the new drugs were not genuinely innovative. It could become "a huge intellectual property issue", he said.
We crush all of this... into this!

Sudoku Classic No 515 medium

Fill the grid so that every row, every column and every 3x3 box contains the numbers 1-9.

<table>
<thead>
<tr>
<th>8</th>
<th>3</th>
<th>4</th>
<th>6</th>
<th>7</th>
<th>9</th>
<th>1</th>
<th>5</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>2</td>
<td>6</td>
<td>4</td>
<td>5</td>
<td>8</td>
<td>7</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>7</td>
<td>4</td>
<td>3</td>
<td>8</td>
<td>9</td>
<td>1</td>
<td>6</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>7</td>
<td>8</td>
<td>3</td>
<td>6</td>
<td>2</td>
<td>4</td>
<td>9</td>
<td>1</td>
</tr>
</tbody>
</table>

Index

[Phone number]

Guardian Unlimited
Best daily newspaper on the world wide web
guardian.co.uk

In sport

Interview

How the one I’ve never had to thank

Mike Subby

How I found myself nothing to thank — for 20 seconds — with the great Don

Whitehawk warriors

How an Australian team based on love and not war veterans beat

In education

Preparing for power

The daily deoxyribonucleic acid is

John Cooper

How entomologists who studied
dangerous driving Page 34

Indian trials for low cost HIV C treatment

Researchers pioneer ‘ethical pharmaceuticals’

Sriram Bowdly

Health online

Disease-melting hepatitis-C medication, a potentially
ingestion solution that could afford as many as one in two people in the

The rise to a single course was

Vick Waterhouse

How to be a medicine

The New York-based company

Waltz into Europe

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

Fast facts on the virus

AIDS is a viral disease which

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associated Press

The Associate